Abatacept for Treatment of Rheumatoid Arthritis: Special Focus on the Elderly

Leading Article
  • 67 Downloads

Abstract

Targeted therapies have been developed for patients with rheumatoid arthritis (RA) for whom prior treatment with traditional disease-modifying anti-rheumatic drugs has failed. The numerous different signaling pathways now targeted by various classes of monoclonal antibodies and small molecule inhibitors may complicate treatment decisions. Abatacept selectively modulates a co-stimulatory signal necessary for T-cell activation. Thus, abatacept is effective in biologic-naive patients and in those for whom biologic therapy has failed. Emerging evidence indicates different benefits depending on patient and disease characteristics. In RA, the clinical goal should be clinical and radiographic remission to prevent structural damage and functional impairment. Nevertheless, the management of elderly patients with RA is often less aggressive, and the treat-to-target strategy is less respected in this age category than in the treatment of RA in younger patients. However, abatacept treatment in elderly patients is as effective and well-tolerated as in younger patients. This review summarizes recently published data on pharmacological properties; clinical and biological data on efficacy, drug retention, and safety, focusing on age; and evidence-based criteria for choosing abatacept or an alternative targeted therapy.

Notes

Compliance with Ethical Standards

Funding

This article did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest

Martin Soubrier, Clément Lahaye, and Zuzana Tatar have no conflicts of interest.

References

  1. 1.
    Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15–25.CrossRefPubMedGoogle Scholar
  2. 2.
    Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984;27(8):864–72.CrossRefPubMedGoogle Scholar
  3. 3.
    Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107(9):1303–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.CrossRefPubMedGoogle Scholar
  5. 5.
    EMA. About. What is Orencia and what is it used for? http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000701/humah_med_000958.jsp&mid=WC0b01ac058001d124. Accessed 15 Jan 2017. (last updated 9 Aug 2017)
  6. 6.
    Keating GM. Abatacept: a review of its use in the management of rheumatoid arthritis. Drugs. 2013;73(10):1095–119.CrossRefPubMedGoogle Scholar
  7. 7.
    Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77.CrossRefPubMedGoogle Scholar
  8. 8.
    Genovese MC, Tena CP, Covarrubias A, Leon G, Mysler E, Keiserman M, et al. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial. J Rheumatol. 2014;41(4):629–39.CrossRefPubMedGoogle Scholar
  9. 9.
    Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 2011;63(10):2854–64.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Bathon J, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis. 2011;70(11):1949–56.CrossRefPubMedGoogle Scholar
  11. 11.
    Smolen JS, Wollenhaupt J, Gomez-Reino JJ, Grassi W, Gaillez C, Poncet C, et al. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). Arthritis Res Ther. 2015;11(17):157.CrossRefGoogle Scholar
  12. 12.
    Wells AF, Westhovens R, Reed DM, Fanti L, Becker J-C, Covucci A, et al. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. J Rheumatol. 2011;38(11):2362–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68(12):1870–7.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barré E, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74(1):19–26.CrossRefPubMedGoogle Scholar
  15. 15.
    Peterfy C, Burmester GR, Bykerk VP, Combe BG, DiCarlo JC, Furst DE, et al. Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis. Ann Rheum Dis. 2016;75(8):1501–5.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kremer JM, Peterfy C, Russell AS, Emery P, Abud-Mendoza C, Sibilia J, et al. Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial. J Rheumatol. 2014;41(6):1077–87.CrossRefPubMedGoogle Scholar
  17. 17.
    Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis. 2011;70(10):1826–30.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008;58(4):953–63.CrossRefPubMedGoogle Scholar
  19. 19.
    Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144(12):865–76.CrossRefPubMedGoogle Scholar
  20. 20.
    Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. Ann Rheum Dis. 2011;70(11):2003–7.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67(8):1096–103.CrossRefPubMedGoogle Scholar
  22. 22.
    Genovese MC, Schiff M, Luggen M, Le Bars M, Aranda R, Elegbe A, et al. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J Rheumatol. 2012;39(8):1546–54.CrossRefPubMedGoogle Scholar
  23. 23.
    Genovese MC, Schiff M, Luggen M, Becker J-C, Aranda R, Teng J, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008;67(4):547–54.CrossRefPubMedGoogle Scholar
  24. 24.
    Genovese MC, Becker J-C, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114–23.CrossRefPubMedGoogle Scholar
  25. 25.
    Keystone EC, Kremer JM, Russell A, Box J, Abud-Mendoza C, Elizondo MG, et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis. 2012;71(6):857–61.CrossRefPubMedGoogle Scholar
  26. 26.
    Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009;68(11):1708–14.CrossRefPubMedGoogle Scholar
  27. 27.
    Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86–94.CrossRefPubMedGoogle Scholar
  28. 28.
    Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013;65(1):28–38.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Finckh A, Neto D, Iannone F, Loza E, Lie E, van Riel P, et al. The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries. RMD Open. 2015;1(1):e000040.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Nüßlein HG, Alten R, Galeazzi M, Lorenz H-M, Nurmohamed MT, Bensen WG, et al. Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. Clin Exp Rheumatol. 2016;34(3):489–99.PubMedGoogle Scholar
  31. 31.
    Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, Schaeverbeke T, et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the “Orencia and Rheumatoid Arthritis” registry. Ann Rheum Dis. 2012;71(11):1815–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Cañete JD, Hernández MV, Sanmartí R. Safety profile of biological therapies for treating rheumatoid arthritis. Expert Opin Biol Ther. 2017;17(9):1089–103.CrossRefPubMedGoogle Scholar
  33. 33.
    Singh JA, Hossain A, Mudano AS, Tanjong Ghogomu E, Suarez-Almazor ME, Buchbinder R, et al. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017;5:CD012657.Google Scholar
  34. 34.
    Singh JA, Hossain A, Tanjong Ghogomu E, Mudano AS, Maxwell LJ, Buchbinder R, et al. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017;3:CD012591.Google Scholar
  35. 35.
    Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ. 2009;181(11):787–96.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Weinblatt ME, Moreland LW, Westhovens R, Cohen RB, Kelly SM, Khan N, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol. 2013;40(6):787–97.CrossRefPubMedGoogle Scholar
  37. 37.
    Alten R, Kaine J, Keystone E, Nash P, Delaet I, Genovese MC. Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment. Arthritis Rheumatol (Hoboken, NJ). 2014;66(8):1987–97.Google Scholar
  38. 38.
    Simon TA, Askling J, Lacaille D, Franklin J, Wolfe F, Covucci A, et al. Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment. Arthritis Res Ther. 2010;12(2):R67.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Salmon JH, Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, et al. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry. Ann Rheum Dis. 2016;75(6):1108–13.CrossRefPubMedGoogle Scholar
  40. 40.
    Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;15(17):212.CrossRefGoogle Scholar
  41. 41.
    Lahaye C, Tatar Z, Dubost J-J, Soubrier M. Overview of biologic treatments in the elderly. Jt Bone Spine. 2015;82(3):154–60.CrossRefGoogle Scholar
  42. 42.
    Soubrier M, Mathieu S, Payet S, Dubost J-J, Ristori J-M. Elderly-onset rheumatoid arthritis. Jt Bone Spine. 2010;77(4):290–6.CrossRefGoogle Scholar
  43. 43.
    Huscher D, Sengler C, Gromnica-Ihle E, Bischoff S, Eidner T, Ochs W, et al. Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: a matched-pairs analysis taking age and disease duration into account. Clin Exp Rheumatol. 2013;31(2):256–62.PubMedGoogle Scholar
  44. 44.
    Innala L, Berglin E, Möller B, Ljung L, Smedby T, Södergren A, et al. Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2014;16(2):R94.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Sekiguchi M, Fujii T, Matsui K, Murakami K, Morita S, Ohmura K, et al. Differences in predictive factors for sustained clinical remission with abatacept between younger and elderly patients with biologic-naive rheumatoid arthritis: results from the ABROAD Study. J Rheumatol. 2016;43(11):1974–83.CrossRefPubMedGoogle Scholar
  46. 46.
    Krams T, Ruyssen-Witrand A, Nigon D, Degboe Y, Tobon G, Fautrel B, et al. Effect of age at rheumatoid arthritis onset on clinical, radiographic, and functional outcomes: the ESPOIR cohort. Jt Bone Spine. 2016;83(5):511–5.CrossRefGoogle Scholar
  47. 47.
    Mueller RB, Kaegi T, Finckh A, Haile SR, Schulze-Koops H, von Kempis J, et al. Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort. Rheumatology (Oxford). 2014;53(4):671–7.CrossRefGoogle Scholar
  48. 48.
    Soubrier M, Tatar Z, Couderc M, Mathieu S, Dubost J-J. Rheumatoid arthritis in the elderly in the era of tight control. Drugs Aging. 2013;30(11):863–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol. 2010;49(3):239–48.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Souverein PC, Berard A, Van Staa TP, Cooper C, Egberts ACG, Leufkens HGM, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90(8):859–65.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Filippini M, Bazzani C, Favalli EG, Marchesoni A, Atzeni F, Sarzi-Puttini P, et al. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol. 2010;38(2–3):90–6.CrossRefPubMedGoogle Scholar
  52. 52.
    Fleischmann R, Iqbal I. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging. 2007;24(3):239–54.CrossRefPubMedGoogle Scholar
  53. 53.
    Hyrich KL, Watson KD, Silman AJ, Symmons DPM, British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006;45(12):1558–65.CrossRefGoogle Scholar
  54. 54.
    Genevay S, Finckh A, Ciurea A, Chamot A-M, Kyburz D, Gabay C, et al. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2007;57(4):679–85.CrossRefPubMedGoogle Scholar
  55. 55.
    Radovits BJ, Kievit W, Fransen J, van de Laar MA, Jansen TL, van Riel PL, Laan RF, et al. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68(9):1470–3.CrossRefPubMedGoogle Scholar
  56. 56.
    Radovits BJ, Fransen J, van Riel PLCM, Laan RFJM. Influence of age and gender on the 28-joint Disease Activity Score (DAS28) in rheumatoid arthritis. Ann Rheum Dis. 2008;67(8):1127–31.CrossRefPubMedGoogle Scholar
  57. 57.
    Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol. 2006;33(2):234–43.PubMedGoogle Scholar
  58. 58.
    Köller MD, Aletaha D, Funovits J, Pangan A, Baker D, Smolen JS. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. Rheumatology (Oxford). 2009;48(12):1575–80.CrossRefGoogle Scholar
  59. 59.
    Payet S, Soubrier M, Perrodeau E, Bardin T, Cantagrel A, Combe B, et al. Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry. Arthritis Care Res (Hoboken). 2014;66(9):1289–95.CrossRefPubMedGoogle Scholar
  60. 60.
    Pers Y-M, Schaub R, Constant E, Lambert J, Godfrin-Valnet M, Fortunet C, et al. Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis. Jt Bone Spine. 2015;82(1):25–30.CrossRefGoogle Scholar
  61. 61.
    Curtis JR, Schulze-Koops H, Takiya L, Mebus CA, Terry KK, Biswas P, et al. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis. Clin Exp Rheumatol. 2017;35(3):390–400.PubMedGoogle Scholar
  62. 62.
    Leon L, Gomez A, Vadillo C, Pato E, Rodriguez-Rodriguez L, Jover JA, Abasolo L. Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis inclinical practice. Clin Exp Rheumatol. 2018;36(1):29–35.PubMedGoogle Scholar
  63. 63.
    Zhang J, Xie F, Yun H, Chen L, Muntner P, Levitan EB, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1813–8.CrossRefPubMedGoogle Scholar
  64. 64.
    Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Torp-Pedersen C, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis. 2011;70(6):929–34.CrossRefPubMedGoogle Scholar
  65. 65.
    Takahashi N, Kojima T, Asai S, Watanabe T, Matsumoto T, Asai N, Sobue Y, Ishiguro N. Being elderly is not a predictive factor of discontinuation of abatacept due to adverse events in rheumatoid arthritis patients with concomitant methotrexate: a retrospective observational study based on data from a Japanese multicenter registry study [abstract]. Arthritis Rheumatol. 2017;69(suppl 10).Google Scholar
  66. 66.
    Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, et al. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. Ann Rheum Dis. 2015;74(6):1065–71.CrossRefPubMedGoogle Scholar
  67. 67.
    Lahaye C, Soubrier M, Mulliez A, Bardin T, Cantagrel A, Combe B, et al. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology’s ORA registry. Rheumatology (Oxford). 2016;55(5):874–82.CrossRefGoogle Scholar
  68. 68.
    Santé publique France. Surveillance épidémiologique des cancers. 2010. http://invs.santepubliquefrance.fr/Dossiers-thematiques/Maladies-chroniques-ettraumatismes/Cancers/Surveillance-epidemiologique-des-cancers. Accessed 25 Apr 2017.
  69. 69.
    INED. Taux de mortalité par sexe et par age. 2015. https://www.ined.fr/fr/tout-savoirpopulation/chiffres/france/mortalite-cause-deces/taux-mortalite-sexe-age/. Accessed 16 Jun 2017.
  70. 70.
    Matsuda M, Asanuma YF, Kouzu N, Mimura T. Analysis of the efficacy, safety and continuation rate of abatacept in elderly patients with rheumatoid arthritis [abstract]. Arthritis Rheumatol. 2017;69(suppl 10).Google Scholar
  71. 71.
    Frisell T, Baecklund E, Bengtsson K, Di Giuseppe D, Forsblad-d’Elia H, Askling J, ARTIS Study group. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics. Ann Rheum Dis. 2017.  https://doi.org/10.1136/annrheumdis-2017-212395.Google Scholar
  72. 72.
    Kamata Y, Minota S. Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using “National Database of Health Insurance Claims and Specific Health Checkups of Japan”. Rheumatol Int. 2018;38(4):663–8.  https://doi.org/10.1007/s00296-017-3900-5.CrossRefPubMedGoogle Scholar
  73. 73.
    Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol (Hoboken, NJ). 2016;68(1):1–26.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Martin Soubrier
    • 1
    • 2
  • Clement Lahaye
    • 1
  • Zuzana Tatar
    • 3
  1. 1.Rheumatology DepartmentCHU Gabriel MontpiedClermont-FerrandFrance
  2. 2.Faculté de MédecineClermont Université, Université d’AuvergneClermont-FerrandFrance
  3. 3.Rheumatology DepartmentClermont-FerrandFrance

Personalised recommendations